Langenbeck's Archives of Surgery

, Volume 397, Issue 5, pp 697–710

The role of HBIg as hepatitis B reinfection prophylaxis following liver transplantation

  • Arianeb Mehrabi
  • Majid Esmaeilzadeh
  • Hamidreza Fonouni
  • Mohammadreza Hafezi
  • Nuh N. Rahbari
  • Mohammad Golriz
  • Ali Majlesara
  • Morva Tahmasbi Rad
  • Mahmoud Sadeghi
  • Jan Schmidt
  • Tom M. Ganten
Review Article
  • 331 Downloads

Abstract

Background and introduction

Without adequate prophylaxis, liver transplantation (LTx) is frequently followed by hepatitis B virus (HBV) reinfection, which results in rapidly progressing liver disease and significantly decreased overall survival. In the last two decades, significant progress has been made in the prophylaxis and treatment of HBV.

Discussion

We present an overview of different protocols and regimens used for prophylaxis of HBV reinfection after LTx and describe the protocol implemented at our center. Following LTx, HBV reinfection can be effectively prevented by administration of anti-hepatitis B immunoglobulin (HBIg) alone or more recently in combination with antiviral nucleoside/nucleotide analogs (NUCs). Several studies reported good results with the use of HBIg alone, but combination treatment with HBIg and NUCs has proven to be a superior prophylactic regimen for HBV recurrence. At present, combination therapy (HBIg and a nucleoside or nucleotide analog) is the gold standard used in many transplantation centers. This preventive regimen reduces the risk of a recurrence of HBV infection and thereby the need for re-transplantation. Future and ongoing studies will show how long HBIg must be given after transplantation, especially when used in combination with potent antivirals, such as entecavir or tenofovir.

Keywords

HBIg Hepatitis B virus Prophylaxis Liver transplantation Nucleoside/nucleotide analogs 

References

  1. 1.
    Alter MJ (2003) Epidemiology and prevention of hepatitis B. Semin Liver Dis 23:39–46PubMedGoogle Scholar
  2. 2.
    Perz JF, Farrington LA, Pecoraro C, et al. Estimated global prevalence of hepatitis C virus infection [abstract]. In: Abstracts of the Infectious Diseases Society of America 42nd Annual Meeting, Boston, MA, September 2004.Google Scholar
  3. 3.
    WHO. Hepatitis B fact sheet. http://www.who.int/mediacentre/factsheets/fs204/en/. Accessed on: February 2005.
  4. 4.
    Viral hepatitis guidelines in hemodialysis and transplantation. Am J Transplant 2004;4(10):72–82Google Scholar
  5. 5.
    Colombo M, Sangiovani A (2003) Etiology, natural history and treatment of hepatocellular carcinoma. Antivir Res 60:145–150PubMedGoogle Scholar
  6. 6.
    Ben Ari Z, Tur-Kaspa R (1997) New trends in liver transplantation for viral hepatitis. Am J Gastroenterol 92:2155PubMedGoogle Scholar
  7. 7.
    Dodson SF, Issa S, Bonham A (1999) Liver transplantation for chronic viral hepatitis. Surg Clin North Am 79:131PubMedGoogle Scholar
  8. 8.
    Rosen HR (2001) Hepatitis B and C in the liver transplant recipient: current understanding and treatment. Liver Transplant 7:S87–S98Google Scholar
  9. 9.
    Faust D, Rabenau HF, Allwin R et al (2003) Cost-effective and safe ambulatory long term immunoprophylaxis with intramuscular instead f intravenous hepatitis B immunoglobulin to prevent reinfection after orthotopic liver transplantation. Clin Transplant 17:254–258PubMedGoogle Scholar
  10. 10.
    Samuel D (2009) The option of liver transplantation for hepatitis B: where are we? Dig Liver Dis 41(suppl 2):S185–S189PubMedGoogle Scholar
  11. 11.
    Coffin CS, Terrault NA (2007) Management of hepatitis B in liver transplant recipients. J Viral Hepatitis 14(suppl 1):37–44Google Scholar
  12. 12.
    Pan T, Tang L, Yuan J et al (2007) Recombinant anti-HBsAg fab blocks hepatitis B virus infection after orthotopic liver transplantation. Hepatobilliary Pancreat Dis Int 6:370–375Google Scholar
  13. 13.
    Buti M, Antonio M, Prieto M et al (2003) A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin and lamivudine with long term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. J Hepatol 38:811–817PubMedGoogle Scholar
  14. 14.
    Neumann UP, Langrehr JM, Naumann U et al (2002) Impact of HLA compatibilities in patients undergoing liver transplantation for HBV cirrhosis. Clin Transplant 16:122–129PubMedGoogle Scholar
  15. 15.
    Franics MJ, Kane M. Hepatitis B Vaccine, Chapter 10 in Vaccines, 3rd ed. Stanley A. Plotnick and Walter A. Orenstein, eds. W.B. Saunders Company; Philadelphia, 1999 (159–82).Google Scholar
  16. 16.
    Engler SH, Sauer PW, Golling M et al (2001) Immunogenicity of two accelerated hepatitis B vaccination protocols in liver transplant candidates. Eur J Gastroenterol Hepatol 13:363–367PubMedGoogle Scholar
  17. 17.
    Eisenbach C, Sauer P, Mehrabi A et al (2006) Prevention of hepatitis B virus recurrence after liver transplantation. Clin Transplant 20(suppl 17):111–116PubMedGoogle Scholar
  18. 18.
    Riediger C, Berberat PO, Sauer P et al (2007) Prophylaxis and treatment of recurrent viral hepatitis after liver transplantation. Nephrol Dial Transplant 22(Suppl 8):viii37–viii46PubMedGoogle Scholar
  19. 19.
    Wang ZX, Ding GS, Fu H et al (2004) Prevention of hepatitis B virus reinfection after orthotopic liver transplantation. Hepatobiliary Pancreat Dis Int 3:345–348PubMedGoogle Scholar
  20. 20.
    Wang ZF, Liu C (2004) Liver retransplantation: indication and outcome. Hepatobiliary Pancreat Dis Int 3:175–178PubMedGoogle Scholar
  21. 21.
    Zhu JP, Zhang TL, Li L et al (2003) Prevention and treatment of hepatitis B recurrence after liver transplantation. Hepatobiliary Pancreat Dis Int 2:500–503PubMedGoogle Scholar
  22. 22.
    Terrault NA, Zhou S, Combs C et al (1996) Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 24:1327–1333PubMedGoogle Scholar
  23. 23.
    Zheng SS, Wu J, Liang TB et al (2002) Prophylaxis and treatment of hepatitis B virus reinfection following liver transplantation. Hepatobiliary Pancreat Dis Int 1:327–329PubMedGoogle Scholar
  24. 24.
    Samuel D, Feray C, Bismuth H (1997) Hepatitis viruses and liver transplantation. J Gastroenterol Hepatol 12:S335–S341PubMedGoogle Scholar
  25. 25.
    Samuel D, Muller R, Alexander G, Bismuth H et al (1993) Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 329(25):1842–1847PubMedGoogle Scholar
  26. 26.
    Hwang S, Lee SG, Ahn CS et al (2008) Prevention of hepatitis B recurrence after living donor liver transplantation: primary high-dose hepatitis B immunoglobulin monotherapy and rescue antiviral therapy. Liver Transplant 14:770–778Google Scholar
  27. 27.
    Lu Y, Wang B, Yu L et al (2004) Lamivudine in prevention and treatment of recurrent HBV after liver transplantation. Hepatobiliary Pancreat Dis Int 3:504–507PubMedGoogle Scholar
  28. 28.
    Wang ZF, Zhu ZJ, Shen ZY (2005) Advances in prophylaxis and treatment of recurrent hepatitis B after liver transplantation. Hepatobiliary Pancreat Dis Int 4:509–514PubMedGoogle Scholar
  29. 29.
    Papatheodordis GV, Sevastianos V, Burroughs AK (2003) Prevention of and treatment for hepatitis B virus infection after liver transplantation in the nucleoside analogues era. Am J Transpl 3:250–258Google Scholar
  30. 30.
    Mas A (2009) Liver transplantation for hepatitis B virus. Pre-emptive and peri-operative prophylaxis. Dig Liver Dis 41(suppl 2):S191–S194PubMedGoogle Scholar
  31. 31.
    Shouval D, Samuel D (2000) Hepatitis B immune globulin to prevent HBV graft reinfection following liver transplantation: a concise review. Hepatology 32:1189–1195PubMedGoogle Scholar
  32. 32.
    Van Nunen AB, de Man RA, Heijtink RA et al (2002) Passive immunization of chronic hepatitis B patients on lamivudine therapy: a feasible issue? J Viral Hepatitis 9:221–228Google Scholar
  33. 33.
    Liu H, Liu YF (2003) Liver transplantation for patients with viral hepatitis. HBPD Int 2:28–31PubMedGoogle Scholar
  34. 34.
    Baruch Y, Ben-Porath E, Enat R (1994) Immunoprophylaxis with hepatitis B immunoglobulin after liver transplantation, an economical approach. J Hepatol 20:153PubMedGoogle Scholar
  35. 35.
    Hooman N, Rifai K, Hadem J et al (2008) Antibody to hepatitis B surface antigen trough levels and half-lives do not differ after intravenous and intramuscular hepatitis B immunoglobulin administration after liver transplantation. Liver Transplant 14:435–442Google Scholar
  36. 36.
    Kruger M (2000) European hepatitis B immunoglobulin trials: prevention of recurrent hepatitis B after liver transplantation. Clin Transplant 14(suppl 2):14PubMedGoogle Scholar
  37. 37.
    Yao FY, Osorio RW, Roberts JP et al (1999) Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. Liver Transplant Surg 5:491Google Scholar
  38. 38.
    European Medicines Agency: Core SmPC for human normal immunoglobulin for subcutaneous and intramuscular use. CPMP/BPWG/282/00, London 25 July 2002Google Scholar
  39. 39.
    Thürmann PA, Szymanski J, Haffner S et al (2006) Pharmacokinetics and safety of a novel anti-HBs-enriched immunoglobulin in healthy volunteers after subcutaneous and intramuscular administration. Eur J Clin Pharmacol 62:511–512PubMedGoogle Scholar
  40. 40.
    Lee SK, Park JH, Joh JW et al (2000) Prophylaxis against hepatitis B recurrence following liver transplantation in HBs Ag (+) patients. Transplant Proc 32:2248PubMedGoogle Scholar
  41. 41.
    Avolio AW, Nure E, Pompili M et al (2008) Liver transplantation for hepatitis B virus patients: long-term results of three therapeutic approaches. Transplant Proc 40:1961–1964PubMedGoogle Scholar
  42. 42.
    Yilmaz N, Shiffman ML, Todd Stravitz R et al (2008) Prophylaxis against recurrence of hepatitis B virus after liver transplantation: a retrospective analysis spanning 20 years. Liver Int 28:72–78PubMedGoogle Scholar
  43. 43.
    Gugenheim J, Baldini E, Ouzan D et al (1997) Absence of initial viral replication and long-term high dose immunoglobulin administration improve results of hepatitis B virus recurrence prophylaxis after liver transplantation. Transplant Proc 29:517PubMedGoogle Scholar
  44. 44.
    Markowitz JS, Martin P, Conrad AJ et al (1998) Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 28:585–589PubMedGoogle Scholar
  45. 45.
    Ishitani M, McGory R, Dickson R et al (1997) Retransplantation of patients with severe posttransplant hepatitis B in the first allograft. Transplantation 64:410–414PubMedGoogle Scholar
  46. 46.
    Adler R, Safadi R, Caraco Y et al (1999) Comparison of immune reactivity and pharmacokinetics of two hepatitis B immune globulins in patients after liver transplantation. Hepatology 29:1299–1305PubMedGoogle Scholar
  47. 47.
    Neff GW, Sherman KE (2004) Post-transplant hepatitis: HCV and HBV. Current Hepatitis Reports 3:98–104Google Scholar
  48. 48.
    Angeli P, Scaglione F (2008) Nephrotoxicity of intravenous immunoglobulin in the setting of liver transplantation or HBV-related cirrhosis: an undervalued topic. Minerva Gastroenterol Dietol 54:259–275PubMedGoogle Scholar
  49. 49.
    Habib S, Shaikh OS (2007) Hepatitis B immune globulin. Drug Today 43:379Google Scholar
  50. 50.
    Golling M, Arnold JC, Rudek B et al (1998) HBV prophylaxis: cost/benefit analysis following liver transplantation for HBV-positive liver cirrhosis. Transplant Proc 30:3316–3317PubMedGoogle Scholar
  51. 51.
    Angus PW, Patterson SJ (2008) Liver transplantation for hepatitis B: what is the best hepatitis B immune globulin/antiviral regimen? Liver Transplant 14:S15–S22Google Scholar
  52. 52.
    Deeney HN, Dusheiko GM (2009) Lamivudine combined with hepatitis B immunoglobulin in for prophylaxis of hepatitis B recurrence after liver transplantation: time for a change? Transpl Int 22:385–386PubMedGoogle Scholar
  53. 53.
    Rosenau J, Kreutz TH, Kujawa M et al (2007) HBsAg level at time of liver transplantation determines HBsAg decrease and anti-HBs increase and affects HBV DNA decrease during early immunoglobulin administration. J Hepatol 46:635–644PubMedGoogle Scholar
  54. 54.
    Lenci I, Tisone G, Di Paolo D et al (2008) Total and covalently closed circular DNA detection in post liver transplant liver biopsies of HBV positive patients who underwent liver transplantation with undetectable viraemia. Hepatology 44:573AGoogle Scholar
  55. 55.
    Dumortier J, Chevallier P, Scoazec JY et al (2003) Combined lamivudine and hepatitis B immunoglobulin for the prevention of hepatitis B recurrence after liver transplantation: long term results. Am J Transplant 3:999–1002PubMedGoogle Scholar
  56. 56.
    Faria LC, Gigou M, Roque-Afonso AM et al (2008) Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. Gastroenterology 134:1890–1899PubMedGoogle Scholar
  57. 57.
    Zoulim F, Radenne S, Ducert CH (2008) Management of patients with decompensated hepatitis B virus association cirrhosis. Liver Transplant 14:S1–S7Google Scholar
  58. 58.
    Cooreman MP, Leroux-Roels G, Paulij WP (2001) Vaccine- and hepatitis B immune globulin-induced escape mutations of hepatitis B virus surface antigen. J Biomed Sci 8(3):237–247PubMedGoogle Scholar
  59. 59.
    Degertekin B, Han SH, Keeffe EB et al (2010) The NIH HBV-OLT Study Group. Impact of virologic breakthrough and HBIG regimen on hepatitis B recurrence after liver transplant ation. Am J Transplant 10:1823–1833PubMedGoogle Scholar
  60. 60.
    Dan YY, Wai CHT, Yeoh KHG et al (2006) Prophylactic strategies for hepatitis B patients undergoing liver transplant: a cost-effectiveness analysis. Liver Transplant 12:736–746Google Scholar
  61. 61.
    Han SH, Martin P, Edelstein M et al (2003) Conversion from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in patients receiving long-term prophylaxis to prevent hepatitis B recurrence after liver transplantation. Liver Transplant 9:182–187Google Scholar
  62. 62.
    Di Paolo D, Tisone G, Piccolo P et al (2004) Low-dose hepatitis B immunoglobulin given “on demand” in combination with lamivudine: a highly cost-effective approach to prevent recurrent hepatitis B virus infection in the long-term follow-up after liver transplantation. Transplantation 77:1203–1208PubMedGoogle Scholar
  63. 63.
    O’Grady JG (1997) Clinical economics review: liver transplantation. Aliment Pharmacol Ther 11:445–451PubMedGoogle Scholar
  64. 64.
    Jiao ZY, Jiao Z (2007) Prophylaxis of recurrent hepatitis b in Chinese patients after liver transplantation using lamivudine combined with hepatitis B immune globulin according to the titer of antibody to hepatitis B surface antigen. Transplant Proc 39:1533–1536PubMedGoogle Scholar
  65. 65.
    Saab S, Ham MY, Stone MA et al (2009) Decision analysis model for hepatitis B prophylaxis one year after liver transplantation. Liver Transplant 15:413–420Google Scholar
  66. 66.
    Gane EJ, Angus PW, Strasser S et al (2007) Lamivudine plus low dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 132:931–937PubMedGoogle Scholar
  67. 67.
    Jiang L, Jiang LS, Cheng NS et al (2009) Current prophylactic strategies against hepatitis B virus recurrence after liver transplantation. World J Gastroenterol 15:2489–2499PubMedGoogle Scholar
  68. 68.
    Dienstag JL, Perrillo RP, Schiff EF et al (1995) A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 333:1657–1661PubMedGoogle Scholar
  69. 69.
    Zoulin F, Trepo C (2000) Is lamivudine effective on precore/core promoter mutants of hepatitis B virus? Hepatology 32:1172–1174Google Scholar
  70. 70.
    Chen RY, Edwards R, Shaw T et al (2003) Effect of the G1896 A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro. Hepatology 37:27–35PubMedGoogle Scholar
  71. 71.
    Fung J, Lai CH-L, Tanaka Y et al (2009) The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBe Ag seroconversion. Am J Gastroenterol 104:1–7Google Scholar
  72. 72.
    Wai CT, Lim SG, Tan KC (2001) Outcome of lamivudine resistant hepatitis B virus infection in liver transplant recipients in Singapore. Gut 48:581PubMedGoogle Scholar
  73. 73.
    Fontana RJ, Keeffe EB, Carey W et al (2002) Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transplant 8:433–439Google Scholar
  74. 74.
    Tenney DJ, Pokornowski K, Rose R et al (2008) Entecavir at five years shows long term maintenance of high genetic barrier to hepatitis B virus resistance. Hepatol Int 2:S76–S77Google Scholar
  75. 75.
    Van Bommel F, Zollner B, Sarrazin C et al (2006) Tenofovir for patients with lamivudine-resistant hepatitis B virus infection and high HBV DNA level during adefovir therapy. Hepatology 44:318–325PubMedGoogle Scholar
  76. 76.
    Lai CL, Leung N, Teo EK et al (2005) A 1-year trial of telbivudine, lamivudine and the combination in patients with hepatitis B antigen-positive chronic hepatitis B. Gastroentrology 129:528–536Google Scholar
  77. 77.
    Angus PW, Patterson SJ, Strasser SI et al (2008) A randomized study of adefovir dipivoxil in place of HBIg in combination with lamivudine as post liver transplantation hepatitis B prophylaxis. Hepatology 48:1460–1466PubMedGoogle Scholar
  78. 78.
    Freshwater DA, Dudley T, Cane P et al (2008) Viral persistence after liver transplantation for hepatitis B virus: a cross-sectional study. Transplantation 85:1105–1111PubMedGoogle Scholar
  79. 79.
    Schiff E, Lai CL, Hadziyannis S et al (2007) Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transplant 13:349Google Scholar
  80. 80.
    Schiff ER, Lai CL, Hadziyannis S et al (2003) Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 38:1419PubMedGoogle Scholar
  81. 81.
    Chang TT, Gish RG, De Man R et al (2006) A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354:1001PubMedGoogle Scholar
  82. 82.
    Kuo A, Dienstag JL, Chung RT (2004) Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. Clin Gastroenterol Hepatol 2:266PubMedGoogle Scholar
  83. 83.
    Hou J, Yin YK, Xu D et al (2008) Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1 year of a randomized, double-blind trial. Hepatology 47:447–454PubMedGoogle Scholar
  84. 84.
    Lai CL, Gane E, Liaw YF et al (2007) Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 357:2576–2588PubMedGoogle Scholar
  85. 85.
    Lee PH, Hu RH, Tsai MK et al (2000) Liver transplantation for patients with hepatitis B: prevention of hepatitis B recurrence by intravenous antihepatitis B immunoglobulin and lamivudine. Transplant Proc 32:2245–2247PubMedGoogle Scholar
  86. 86.
    Engler S, Sauer P, Klar E et al (2002) Prophylaxis of hepatitis B recurrence after liver transplantation with lamivudin and hepatitis B immunoglobulin. Transplant Proc 34:2285–2287PubMedGoogle Scholar
  87. 87.
    Steinmuller T, Seehofer D, Rayes N et al (2002) Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology 35:1528PubMedGoogle Scholar
  88. 88.
    Katze L, Paul M, Guy D et al (2008) Prevention of recurrent hepatitis B virus infection after liver transplantation. HBIg antiviral drugs or both? Systematic review and meta analysis. Hepatology 48:573AGoogle Scholar
  89. 89.
    Rizzetto M, Marzano A (2000) Posttransplantation prevention and treatment of recurrent hepatitis B. Liver Transplant 6(Suppl 2):S47–S51Google Scholar
  90. 90.
    Avery PK, Michaels M (2008) Update on immunizations in solid organ transplant recipients: what clinicians need to know? Am J Transpl 8:9–14Google Scholar
  91. 91.
    Gunther M, Neuhaus R, Bauer T et al (2006) Immunization with an adjuvant hepatitis B vaccine in liver transplant recipients: antibody decline and booster vaccination with conventional vaccine. Liver Transplant 12:316–319Google Scholar
  92. 92.
    Di Paolo D, Lenci I, Trinito MO et al (2006) Extended double- dosage HBV vaccination after liver transplantation is ineffective in the absence of lamivudine and prior wash-out of human hepatitis B immunoglobulins. Dig Liver Dis 38:749–754PubMedGoogle Scholar
  93. 93.
    Rosenau J, Hooman N, Hadem J et al (2007) Failure of hepatitis B vaccination with conventional HBsAg vaccine in patients with continuous HBIG prophylaxis after liver transplantation. Liver Transplant 13:367–373Google Scholar
  94. 94.
    Rosenau J, Hooman N, Rifai K et al (2006) Hepatitis B virus immunization with an adjuvant containing vaccine after liver transplantation for hepatitis B-related disease: failure of humoral and cellular immune response. Euro Soc Organ Transplant 19:828–833Google Scholar
  95. 95.
    Bauer T, Günther M, Bienzle U et al (2007) Vaccination against hepatitis B in liver transplantation recipients: pilot analysis of cellular immune response shows evidence of HBs Ag specific regulatory T cells. Liver Transplant 13:434–442Google Scholar
  96. 96.
    Sanchez-Fueyo A, Rimola A, Grande L et al (2000) Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: a new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation. Hepatology 31:496PubMedGoogle Scholar
  97. 97.
    Angelico M, Di Paolo D, Trinito MO et al (2002) Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis. Hepatology 35:176PubMedGoogle Scholar
  98. 98.
    Cornberg M, Protzer U, Dollinger MM et al (2007) Prophylaxis, diagnosis and therapy of hepatitis-B-virus-(HBV-) infection: upgrade of the guideline, AWMF-Register 021/011. Z Gastroenterol 45:525–574PubMedGoogle Scholar
  99. 99.
    Cornberg M, Protzer U, Dollinger MM et al (2008) The German guideline for the management of hepatitis B virus infection. J Viral Hepatitis 15:1–20Google Scholar
  100. 100.
    Bienzle U, Gunther M, Neuhaus R et al (2003) Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease. Hepatology 38:811–819PubMedGoogle Scholar
  101. 101.
    Chang SH, Suh KS, Yi NJ et al (2003) Active immunization against de novo hepatitis B virus infection in pediatric patients after liver transplantation. Hepatology 37:1329PubMedGoogle Scholar
  102. 102.
    Serrano B, Bayas JM, Bruni L et al (2007) Solid organ transplantation and response to vaccination. Vaccine 25:7331PubMedGoogle Scholar
  103. 103.
    Loinaz C, de Juanes JR, Gonzalez EM et al (1997) Hepatitis B vaccination results in 140 liver transplant recipients. Hepatogastroenterology 44:235PubMedGoogle Scholar
  104. 104.
    Dahmen U, Dirsch O, Li J et al (2004) Adoptive transfer of immunity: a new strategy to interfere with severe hepatitis virus reinfection after woodchuck liver transplantation. Transplantation 77:965–972PubMedGoogle Scholar
  105. 105.
    Shouval D (2007) Adoptive transfer of immunity to HBV in liver transplant patients: a step forward toward the proof of concept for therapeutic vaccination or a transient immunologic phenomenon? Liver Transplant 13:14–17Google Scholar
  106. 106.
    Luo Y, Lo CM, Cheung CK et al (2007) Identification of hepatitis B virus-specific lymphocytes in human liver grafts from HBV-immune donors. Liver Transplant 13:71–79Google Scholar
  107. 107.
    Lo CM, Lau GK, Chan SC et al (2007) Efficacy of a pre-S containing vaccine in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B. Am J Transplant 7:434–439PubMedGoogle Scholar
  108. 108.
    Vandepapeliere P, Lau GK, Leroux-Roels G et al (2007) Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. Vaccine 25:8585–8597PubMedGoogle Scholar
  109. 109.
    Schumann A, Fiedler M, Dahmen U et al (2007) Cellular and humoral immune response to a third generation hepatitis B vaccine. J Viral Hepat 14:592–598PubMedGoogle Scholar
  110. 110.
    Protzer-Knolle U, Naumann U, Bartenschlager R et al (1998) Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology 27:254–263PubMedGoogle Scholar
  111. 111.
    Samuel D, Bismuth A, Serres C et al (1991) HBV infection after liver transplantation in HBsAg positive patients: experience with long-term immunoprophylaxis. Transplant Proc 23:1492–1494PubMedGoogle Scholar
  112. 112.
    Buti M, Mass A, Prieto M et al (2000) Rabdomized clinical trial of lamivudine vs. lamivudine+hepatitis B gammaglobulin in the prevention of HBV recurrence after liver transplant-preliminary results. Hepatology 32:217AGoogle Scholar
  113. 113.
    Roque-Afonso AM, Feray C, Samuel D et al (2002) Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors. Gut 50:95–99PubMedGoogle Scholar
  114. 114.
    Roche B, Samuel D, Roque AM et al (1999) J Hepatol 30(Suppl 1):80Google Scholar
  115. 115.
    Yoshida EM, Erb SR, Partovi N et al (1999) Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low dose hepatitis B immune globulin. Liver Transplant Surg 5:520–525Google Scholar
  116. 116.
    Dodson SF, Bonham CA, Geller DA et al (1999) Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors. Transplantation 68:1058–1061PubMedGoogle Scholar
  117. 117.
    Angus PW, McCaughen GW, Gane EJ et al (2000) Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against post transplantation hepatitis B. Liver Transplant 6:429–433Google Scholar
  118. 118.
    Han SH, Ofman J, Holt C et al (2000) An efficacy and cost effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transplant 6:741Google Scholar
  119. 119.
    Anselmo DM, Ghobrial RM, Jung LC et al (2002) New era of liver transplantation for hepatitis B: a 17 year single-center experience. Ann Surg 235:611–619PubMedGoogle Scholar
  120. 120.
    Rosenau J, Bahr MJ, Tillmann HL et al (2001) Lamivudine and low dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role to transplantation as a risk factor for reinfection. J Hepatol 34:895–902PubMedGoogle Scholar
  121. 121.
    Marzano A, Salizzoni M, Debernardi-Venon W et al (2001) Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 34:903–910PubMedGoogle Scholar
  122. 122.
    Seehofer D, Rayes N, Steinmüller T et al (2002) Combination prophylaxis with Hepatitis B immunoglobulin and lamivudine after liver transplantation minimizes HBV recurrence rates unless evolution of pretransplant lamivudine resistance. Z Gastroenterol 40:795–799PubMedGoogle Scholar
  123. 123.
    Lee KW, Lee DS, Lee HH et al (2004) Prevention of de novo hepatitis B infection from HbcAb-positive donors in living donor liver transplantation. Transplant Proc 36:2311–2312PubMedGoogle Scholar
  124. 124.
    Ferretti G, Merli M, Ginanni Corradini S et al (2004) Low-dose intramuscular hepatitis B immune globulin and lamivudine for long-term prophylaxis of hepatitis B recurrence after liver transplantation. Transplant Proc 36:535–538PubMedGoogle Scholar
  125. 125.
    Neff GW, O’Brien CB, Nery J et al (2004) Outcomes in liver transplant recipients with hepatitis B virus: resistance and recurrence patterns from a large transplant center over the last decade. Liver Transplant 10:1372–1378Google Scholar
  126. 126.
    Dickson RC, Terrault NA, Ishitani M et al (2006) Protective antibody levels and dose requirements for IV 5% Nabi hepatitis B immune globulin combined with lamivudine in liver transplantation for hepatitis B-induced end stage liver disease. Liver Transplant 12:124–133Google Scholar
  127. 127.
    Yan ML, Yan LN, Li B et al (2006) Intramuscular hepatitis B immune globulin combined with lamivudine in prevention of hepatitis B recurrence after liver transplantation. Hepatobiliary Pancreat Dis Int 5:360–363PubMedGoogle Scholar
  128. 128.
    Zheng S, Chen Y, Liang T et al (2006) Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B immunoglobulin prophylaxis. Liver Transplant 12:253–258Google Scholar
  129. 129.
    Wong SN, Chu CJ, Wai CT et al (2007) Low risk of hepatitis B virus recurrence after withdrawal of long term hepatitis B immunoglobulin in patients receiving maintenance nucleoside analogue therapy. Liver Transplant 13:374–381Google Scholar
  130. 130.
    Akyildiz M, Karasu Z, Zeytunlu M et al (2007) Adefovir dipivoxil therapy in liver transplant recipients for recurrence of hepatitis B virus infection despite lamivudine plus hepatitis B immunoglobulin prophylaxis. J Gastroenterol Hepatol 22:2130–2134PubMedGoogle Scholar
  131. 131.
    Iacob S, Hrehoret D, Matei E et al (2008) Costs and efficacy of “on demand” low-dose immunoprophylaxis in HBV transplanted patients: experience in the Romanian program of liver transplantation. J Gastrointestin Liver Dis 17:383–388PubMedGoogle Scholar
  132. 132.
    Woo HY, Choi JY, Jang JW et al (2008) Role of long-term lamivudine treatment of hepatitis B virus recurrence after liver transplantation. J Med Virol 80:1891–1899PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Arianeb Mehrabi
    • 1
  • Majid Esmaeilzadeh
    • 1
  • Hamidreza Fonouni
    • 1
  • Mohammadreza Hafezi
    • 1
  • Nuh N. Rahbari
    • 1
  • Mohammad Golriz
    • 1
  • Ali Majlesara
    • 1
  • Morva Tahmasbi Rad
    • 1
  • Mahmoud Sadeghi
    • 2
  • Jan Schmidt
    • 1
  • Tom M. Ganten
    • 3
  1. 1.Department of General, Visceral and Transplantation SurgeryUniversity of HeidelbergHeidelbergGermany
  2. 2.Department of Transplantation ImmunologyUniversity of HeidelbergHeidelbergGermany
  3. 3.Department of Gastroenterology, Hepatology and Infectious DiseasesUniversity of HeidelbergHeidelbergGermany

Personalised recommendations